Anti Malarial Drugs Market Growth Trends And Forecast: Market Size & Forecast 2026

The anti-malarial drugs market covers prescription and prophylactic medicines targeting Plasmodium falciparum and P. vivax infections across both endemic and travel-medicine settings. Global revenue sits at roughly USD 1.0-1.1 billion in 2025, with consensus forecasts placing the market between USD 1.5 billion and USD 1.8 billion by 2033-2034. ACTs, derived from the artemisinin compound first isolated in the 1970s, account for the largest share of therapeutic volume and value.

• •2025 market size: approximately USD 1.05 billion worldwide.
• •Long-term CAGR: roughly 4.1%-5.3% depending on forecast horizon.
• •ACTs remain the WHO-recommended first-line therapy for uncomplicated falciparum malaria.

Demand is anchored by the continued public-health burden of malaria, which the WHO estimates affects hundreds of millions of people annually, with sub-Saharan Africa accounting for the overwhelming majority of cases and deaths. Public-sector procurement funded by donors such as the Global Fund, PMI, and Gavi underwrites stable volume, while pediatric formulation rollouts widen treatment access. A third structural driver is the spread of artemisinin partial resistance in parts of Southeast Asia and emerging signals in Africa, which is pushing investment into new actives and triple-ACT regimens.

• •Persistent endemic burden in WHO African and South-East Asian regions.
• •Donor-funded procurement programs supporting public-sector volumes.
• •Rising artemisinin and partner-drug resistance accelerating pipeline investment.

By drug class, the market is led by artemisinin derivatives and ACTs, followed by chloroquine, quinine, sulfadoxine-pyrimethamine, mefloquine, and the 8-aminoquinoline tafenoquine (approved in 2018 for P. vivax radical cure). By indication, treatment of acute infection dominates over prophylaxis. Geographically, Africa represents the largest volume market due to disease prevalence, while Asia-Pacific delivers the fastest growth as India, Indonesia, and Myanmar scale elimination programs; North America and Europe are smaller but profitable segments driven by travel prophylaxis and vivax treatment.

• •Africa leads in volume; Asia-Pacific shows the strongest forecast growth.
• •ACTs and artemisinin derivatives dominate by drug class.
• •Treatment regimens outweigh prophylactic use in revenue terms.

What are the recent trends and outlook?

Pipeline activity is concentrated on next-generation ACTs, triple-combination therapies, and single-dose tafenoquine regimens that can replace the current 14-day primaquine course for P. vivax. Vaccine rollouts of RTS,S/AS01 (Mosquirix) and the more recent R21/Matrix-M are expected to complement rather than substitute drug therapy, with chemoprevention continuing in children and during seasonal peaks. Through the early 2030s, the market is expected to grow steadily at mid-single digits, supported by donor funding, resistance-driven product innovation, and broader access to pediatric formulations.

• •Triple-ACTs and new tafenoquine regimens are advancing through late-stage development.
• •RTS,S and R21 vaccines complement drug-based control strategies.
• •Mid-single-digit annual growth is expected to continue through 2033.